BiotechTube
Home/Pipeline/Ibrexafungerp (SCY-078)

Ibrexafungerp (SCY-078)

Invasive Candidiasis / Invasive Fungal Infections

Phase 3Development rights with GSK

Key Facts

Indication
Invasive Candidiasis / Invasive Fungal Infections
Phase
Phase 3
Status
Development rights with GSK
Company
Scynexis, Scynexis

About Scynexis

Scynexis is committed to protecting the world against dangerous and difficult-to-treat fungal pathogens, a mission driven by its innovative 'fungerp' platform. The company achieved a significant milestone with the FDA approval and subsequent partnership with GSK for BREXAFEMME® (ibrexafungerp) for vulvovaginal candidiasis. Its strategic focus now includes advancing its second-generation fungerp, SCY-247, through clinical development for serious invasive infections, addressing the critical global threat of antimicrobial resistance.

View full company profile

About Scynexis

Scynexis is committed to protecting the world against dangerous and difficult-to-treat fungal pathogens, a mission driven by its innovative 'fungerp' platform. The company achieved a significant milestone with the FDA approval and subsequent partnership with GSK for BREXAFEMME® (ibrexafungerp) for vulvovaginal candidiasis. Its strategic focus now includes advancing its second-generation fungerp, SCY-247, through clinical development for serious invasive infections, addressing the critical global threat of antimicrobial resistance.

View full company profile

Therapeutic Areas

Infectious DiseaseAntifungalWomen's Health